Lilly Names New Business Leaders
14 September 2009 - 11:30PM
PR Newswire (US)
INDIANAPOLIS, Sept. 14 /PRNewswire-FirstCall/ -- In conjunction
with today's announcement of a new operating model to speed
innovative medicines to patients, Eli Lilly and Company (NYSE:LLY)
has named the leaders of its Development Center of Excellence and
its five business units: oncology, diabetes, established markets,
emerging markets, and Elanco animal health. These leaders will
provide improved line of sight to Lilly's customers. Each will
carry clear decision-making authority and accountability for their
respective parts of the business. The new leaders are: Tim Garnett,
M.D., and Tom Verhoeven, Ph.D., will lead the Development Center of
Excellence within Lilly Research Laboratories. Garnett will have
responsibility for medical, regulatory, global product safety,
translational medicine and global health outcomes. Verhoeven will
have responsibility for the clinical development organization,
product R&D, toxicology/ADME and project management. John H.
Johnson will lead the oncology business unit. Johnson currently
serves as chief executive officer of ImClone Systems, a
wholly-owned subsidiary of Lilly. Enrique A. Conterno will lead the
diabetes business unit. Conterno currently serves as president of
Lilly USA, the company's U.S. business operations. Bryce D. Carmine
will lead the established markets business unit. Carmine currently
serves as Lilly's executive vice president of global marketing and
sales. Jacques Tapiero will lead the emerging markets business
unit. Tapiero currently serves as Lilly's president of the
intercontinental region. Jeffrey N. Simmons will lead Elanco, the
animal health business unit, where he currently serves as
president. Appointments for each of the four pharmaceutical
business unit leaders and the two leaders of the Development Center
of Excellence will become effective on November 1, 2009. "These are
proven leaders who bring a wealth of experience and knowledge to
their respective roles," said John C. Lechleiter, Ph.D., Lilly
chairman, president and chief executive officer. "Each has
demonstrated strong leadership and an ability to get results
throughout their business careers. Moving forward, these
individuals will play a critical role in the success of Lilly's new
operating model." Lechleiter also outlined the details of the
Development Center of Excellence, while explaining the criteria
used to establish Lilly's new business units: -- Development Center
of Excellence - With over 60 molecules in clinical development, the
Development Center of Excellence (COE) will be tasked with
streamlining the development of pipeline molecules and speeding
innovative medicines to patients. The ultimate goal of the
Development COE is to accelerate the launch of important Lilly
molecules over the next decade and bring innovative medicines to
patients sooner. -- Oncology - With the acquisition of ImClone and
the progression of its own pipeline, Lilly remains intent on
building an oncology powerhouse. Currently, one-third of the
company's pipeline is composed of molecules to treat various forms
of cancer. The need for new and better treatments is staggering:
the World Health Organization estimates 12 million cancer-related
deaths per year by 2030. -- Diabetes - Lilly has long been a leader
in diabetes care, with a dedicated asset base and a portfolio of
commercially successful products and promising pipeline
opportunities. The need for new and improved treatments for
patients with diabetes is great: an estimated 246 million adults
are affected worldwide. In addition, Lilly remains one of only a
few global insulin suppliers. -- Established Markets - Lilly's
other important therapeutic areas, including neuroscience,
osteoporosis/bone and cardiovascular, are included in the
established markets business unit. The established markets business
unit will have geographic responsibility for these therapeutic
areas in the United States, Japan, the European Union, Canada, and
Australia / New Zealand. This business unit will also host Lilly's
global marketing organization. -- Emerging Markets - The emerging
markets business unit will include many of the world's
fastest-growing markets, such as China, Russia, Brazil, Mexico,
South Korea and Turkey. Lilly aims to increase its presence in
these countries and others where strong growth rates for
pharmaceuticals are projected over the next decade. The creation of
an emerging markets business unit will increase the company's focus
on these areas and best position Lilly to serve growing patient
needs among two-thirds of the world's population. -- Elanco Animal
Health - Lilly remains committed to its animal health business.
Elanco sales continue to grow at a rate faster than the overall
animal health market. Elanco is positioned to deliver double-digit
earnings growth over the next five years, bolstered by several
recent acquisitions and the launch of its companion animal
business. Additional details about the new leaders of Lilly's
Development Center of Excellence and five business units: Dr. Tim
Garnett is currently chief medical officer and senior vice
president of global medical, regulatory and safety for Lilly.
During his 11-year tenure at Lilly, Garnett has served as vice
president for global patient safety; global brand development
leader; as group medical director responsible for the development
of duloxetine; and European clinical research physician for
raloxifene. Prior to joining Lilly, Garnett acquired seven years of
experience, holding a variety of positions in the pharmaceutical
industry in Europe with Organon Laboratories. Garnett qualified in
medicine at St. George's Hospital in London. He practiced
obstetrics and gynecology for eight years prior to joining the
pharmaceutical industry and conducted clinical research into
menopause, premenstrual tension and postmenopausal osteoporosis. He
is a fellow of the Royal College of Obstetricians and Gynecologists
in the United Kingdom and a fellow of the Faculty of Pharmaceutical
Medicine of the Royal College of Physicians. He is a member of the
Royal Society of Medicine. Thomas Verhoeven, Ph.D., joined Lilly as
vice president for product research and development in June 2003
responsible for the chemical, bioproduct, analytical,
pharmaceutical and devices operations. In 2008, he was promoted to
senior vice president of global product development. His current
responsibilities include management of the therapeutic area
platform teams including neuroscience, diabetes and endocrine,
osteoporosis, oncology, and CV/acute care. He also directs global
clinical operations and health outcomes. This responsibility
includes all of the Phase III development work required for
presubmission of new products and the ongoing development work
required to support life cycle plans for those products already
marketed. Verhoeven is a member of the LRL policy committee, the
portfolio management committee and the corporate operations
committee. He is also chair of the product development committee.
Prior to joining Lilly, Verhoeven worked for Merck Research
Laboratories for 23 years. Within Merck Research Laboratories, he
was responsible for the process development and commercialization
of multiple products across a range of therapeutic classes, global
operations and strategic research planning. Verhoeven received a
bachelor of science degree in chemistry from the University of
Michigan, a doctorate in organic chemistry from the University of
Wisconsin, and an appointment as a National Institutes of Health
(NIH) fellow at Stanford University. John H. Johnson has served as
chief executive officer of ImClone Systems since August 2007. He
also served as a member of the company's board of directors until
the company was acquired by Lilly in November 2008. Prior to
joining ImClone, Johnson served as company group chairman of
Johnson & Johnson's Worldwide Biopharmaceuticals unit. In this
executive role, he was responsible for the Johnson & Johnson
Biotechnology, Immunology and Oncology commercial businesses,
including Centocor, Inc., Ortho Biotech Products, L.P. and the
Worldwide Strategic Marketing group. Earlier in his career, Johnson
held roles of increasing responsibility in sales and sales
management at Pfizer before joining Johnson & Johnson to help
lead their entry into the anti-infectives business. He advanced
through positions of increasing responsibility with Ortho-McNeil,
including leading the commercial groups responsible for the
development of sales, marketing and new product strategies of
several of the company's flagship brands. Johnson received a
bachelor of science degree from East Stroudsburg University of
Pennsylvania. He is also a member of the boards of BioNJ and Cempra
Pharmaceuticals. Enrique A. Conterno was promoted to president of
Lilly USA in January 2009. He is a member of Lilly's operations
committee and senior management council. Prior to his promotion,
Conterno served as senior vice president of health care
professional markets for Lilly USA. Born in Lima, Peru, Conterno
earned a master of business administration degree at Duke
University in 1992. He earned his bachelor's degree in mechanical
engineering from Case Western Reserve University in 1989. Conterno
joined Lilly as a sales representative in 1992. From 1993 to 1995,
he held roles as a financial analyst, marketing associate, and
business development manager. In 1996, Conterno became sales and
marketing director for the Peru affiliate, and in 1998, he became
the sales and marketing director for Lilly's affiliate in Brazil.
In 2000, Conterno was named executive director of marketing for the
intercontinental region and Japan. Conterno served as president and
general manager for Lilly's operations in Mexico in 2003, and was
named vice president of Lilly USA's neuroscience business unit in
July 2006. He serves on the Board of Visitors of the Fuqua School
of Business at Duke University. Bryce D. Carmine was named
executive vice president, global marketing and sales, in April
2008. Prior to this position, Carmine had been president, global
product development, with responsibility for the development of the
late-phase pipeline molecules at Lilly. Prior to assuming this
position, Carmine had a series of leadership roles that related to
overseeing late-phase development of molecules for multiple
therapeutic areas. His current responsibilities include leadership
of the global pharmaceutical marketing and sales organizations
across Lilly. He is a member of the company's executive committee
and operations committee. Born in New Zealand, Carmine received a
bachelor of science in biochemistry from Massey University in 1973.
He joined Lilly in 1975 in New Zealand and subsequently held
several marketing and management positions in New Zealand before
moving in 1983 to the company's corporate headquarters in
Indianapolis. In 1986, he was named general manager of
Daewoong-Lilly Pharmaceutical Company in South Korea, a joint
venture between Lilly and Daewoong. He became managing director of
Lilly operations in Australia in 1989. During his tenure in
Australia, he was actively involved in the Australian
Pharmaceutical Research and Manufacturers Association, holding the
position of chairman from 1992 to 1995. Carmine then served as the
president and general manager of Lilly Japan from 1995 to June 1999
before returning to Indianapolis. Jacques Tapiero was named
president of the intercontinental region for Lilly in November
2004. The intercontinental region comprises offices in Asia,
Australia, Africa and Middle East countries, Canada, Latin America
and Russia. He also is a member of the company's senior management
council. Tapiero had been president and general manager of Lilly
France since December 1999. Born in Morocco, Tapiero is a Swiss
citizen who in 1980 received a master of business administration
degree from the Ecole Superieure de Commerce at Clermond Ferrand in
France. In 1982, he obtained a second master of business
administration degree at the American Graduate School of
International Management in Glendale, Arizona. Tapiero joined Lilly
in 1983 as a financial analyst. He held several sales and finance
positions in Indianapolis, France and Switzerland. He was named
managing director of Lilly Sweden in 1993. From 1995 to 1999,
Tapiero was president and general manager at Lilly Brazil. In late
1999, Tapiero was named president and general manager for Lilly
France. Tapiero is a member of the Thunderbird Global Council, a
council of leading business executives who advise Thunderbird, the
School of Global Management. Jeff N. Simmons was named president of
Elanco, the animal health division of Lilly, in January 2008.
Simmons received a bachelor's degree in agricultural economics and
marketing from Cornell University in 1989. Simmons joined Lilly in
1989 in sales. He has held numerous positions over the last 19
years within Elanco, including executive director of global
strategy, operations and research and development; area director,
Western Europe, based in the United Kingdom; and country director
for Brazil, located in Sao Paulo. He has managed Elanco's
international marketing for cattle and poultry and has also held
other marketing and sales management positions in Elanco's domestic
and international areas. Simmons is a leading spokesperson on the
role of technology in the global food chain, as well as change
leadership and execution in the agricultural and food industries.
He is a member of the Animal Health Institute's executive committee
and is chairman of its board of directors. He is also a member of
Harvard's PAPSAC committee (Private and Public, Scientific,
Academic, and Consumer Food Policy Council) and is chairman of the
FFA Sponsors Board. About Lilly Lilly, a leading innovation-driven
corporation, is developing a growing portfolio of pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers - through medicines and information - for some of the
world's most urgent medical needs. Additional information about
Lilly is available at http://www.lilly.com/. (Logo:
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) C-LLY
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGODATASOURCE: Eli
Lilly and Company CONTACT: Edward G. Sagebiel, +1-317-433-9899,
(Media), or Mark E. Taylor, +1-317-276-5795; (Media), or Philip
Johnson, +1-317-655-6874; (Investors)
Copyright